Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: Results from a phase 2 trial
Open Access
- 18 April 2011
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 86 (8), 640-645
- https://doi.org/10.1002/ajh.22053
Abstract
The combination of lenalidomide and low‐dose dexamethasone is an effective treatment for multiple myeloma (MM). Addition of alkylating agents to lenalidomide or thalidomide results in increased response rates and deeper responses. We designed this trial to study the combination of cyclophosphamide, lenalidomide, and dexamethasone (CRd) as initial therapy for MM. Fifty‐three patients with previously untreated symptomatic MM was enrolled. Patients received 4‐week treatment cycles consisting of lenalidomide (25 mg daily for 3 weeks), dexamethasone (40 mg weekly), and cyclophosphamide (300 mg/m2 weekly for 3 weeks). A partial response or better was seen in 85% of patients including 47% with a very good partial response or better. The toxicities were manageable with over 80% of planned doses delivered; six patients went off study for toxicity. The median progression free survival (PFS) for the entire group was 28 months (95% CI: 22.7–32.6) and the overall survival (OS) at 2 years was 87% (95% CI: 78–96). Importantly, 14 patients with high‐risk MM had similar PFS and OS as the standard‐risk patients (n = 39). CRd is an effective and well‐tolerated regimen for upfront therapy of MM with high response rates and excellent 2‐year OS, and is suitable for long‐term therapy. Am. J. Hematol. 2011.This publication has 32 references indexed in Scilit:
- Multiple myeloma – current issues and controversiesCancer Treatment Reviews, 2010
- Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trialThe Lancet Oncology, 2010
- Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus GuidelinesMayo Clinic Proceedings, 2009
- Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trialLeukemia, 2009
- Treatment of Myeloma: Cure vs ControlMayo Clinic Proceedings, 2008
- Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple MyelomaNew England Journal of Medicine, 2008
- Improved survival in multiple myeloma and the impact of novel therapiesBlood, 2008
- Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomised trialThe Lancet, 2007
- Phase III Clinical Trial of Thalidomide Plus Dexamethasone Compared With Dexamethasone Alone in Newly Diagnosed Multiple Myeloma: A Clinical Trial Coordinated by the Eastern Cooperative Oncology GroupJournal of Clinical Oncology, 2006
- A Phase 2 Study of Bortezomib in Relapsed, Refractory MyelomaNew England Journal of Medicine, 2003